Ipsen pulls cancer drug Tazverik from market over safety risks
Nicole DeFeudis / endpoints - Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...
AI Summary: Ipsen has removed its EZH2 inhibitor Tazverik (tazemetostat) from the U.S. market after safety issues flagged by an independent monitoring review. The withdrawal forces clinicians to pivot to alternative therapies and triggers regulatory and clinical re‑examination of the drug’s benefit‑risk profile for patients previously depending on it.
Related Stories
Bristol Myers Squibb wins first-in-class approval for protein‑degrader myeloma therapy / 15 days
Belzutifan plus pembrolizumab gains approval for adjuvant RCC / 5 wks
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 2 months
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 2 months
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 2 months
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 3 months
Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival / 5 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Venture Capital, Health Disparities, Medical Devices, Weight Loss and look for the RSS link.
StackHealth Time Machine